Ticker
$RARE
1 catalyst touching RARE in the last 60 days, newest first, each with the price move that followed.
- 72
Ultragenyx to sell Rare Pediatric Disease PRV for $210M
Ultragenyx agreed to sell a Rare Pediatric Disease Priority Review Voucher (PRV) awarded by the FDA for approval of GENGLYCOS in glycogen storage disease type Ia for $210 million in cash. PRVs are transferable assets that allow the holder to expedite FDA review of a drug, and the $210M proceeds represent meaningful non-dilutive cash for a specialty pharma company, though 20% ($42M) will go to the NIH under an existing license agreement.
RARE ▲SEC 8-K · 7 Oct 2026, 13:00 UTC
Information only. AURA does not give buy or sell recommendations.